Partnering News

12.10.2019

ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

12.04.2019

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

11.22.2019

CeMM enters into research collaboration on expanding the druggable proteome with Pfizer Inc.

11.13.2019

CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

10.14.2019

ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology

07.31.2019

BioInvent announces selection of first target discovered by BioInvent’s proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.

02.12.2019

G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s Groton, Conn. Site

01.09.2019

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types

01.07.2019

CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery

12.17.2018

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

10.25.2018

CANCER THERAPEUTICS CRC SIGNS AGREEMENT TO ENABLE PFIZER TO DEVELOP NOVEL CANCER DRUGS

09.17.2018

ATOMWISE ENTERS INTO AN EVALUATION AGREEMENT WITH PFIZER